- Home
- RLAY vs BIPC Comparison
RLAY vs BIPC Comparison
Compare RLAY & BIPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | BIPC |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.8B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RLAY | BIPC |
|---|---|---|
| Price | $17.98 | $35.18 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 10 | 1 |
| Target Price | $19.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.9M | 1.1M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | $7.85 |
| Revenue Next Year | $324.03 | $5.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $5.17 | $34.18 |
| 52 Week High | $21.27 | $51.72 |
Technical Indicators
Market Signals| Indicator | RLAY | BIPC |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 36.67 |
| Support Level | $11.68 | $35.10 |
| Resistance Level | $20.29 | $36.58 |
| Average True Range (ATR) | 0.83 | 0.80 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 34.28 | 27.64 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About BIPC Brookfield Infrastructure Corporation
Brookfield Infrastructure Corp is an indirect subsidiary of the partnership of the diversified infrastructure owner and operators. Its business is comprised of a U.K. regulated distribution operation, a Brazilian regulated natural gas transmission operation and an international intermodal logistics operation. Geographically, the company generates a majority of its revenue from Brazil and rest from United Kingdom, United States, France, Switzerland, Singapore, China, Denmark, Hong Kong, Germany and Others.